Clinical Trials | October 13, 2025
Moderna’s mRNA-4359 shows promising early results in resistant Melanoma at ESMO 2025
mRNA-4359 advances to phase 2 following encouraging results in checkpoint inhibitor-resistant Melanoma
mRNA-4359 advances to phase 2 following encouraging results in checkpoint inhibitor-resistant Melanoma
WHO’s global SPECS 2030 target to increase effective refractive error coverage by 40% by 2030
With global certification in place, the Ambernath site expands Supriya’s footprint beyond APIs into high-margin formulations
Both of Moderna's COVID-19 vaccines for the 2025-2026 season have demonstrated strong immune responses against today's top circulating COVID-19 strains
The collaboration is expected to facilitate access to world-class treatments and specialised care for Iraqi personnel
The Moderna Innovation and Technology Centre in Harwell, Oxfordshire is now fully operational and Moderna is licensed to supply British-made COVID-19 vaccines to the UK population
All drug substance for Moderna’s authorized Spikevax (COVID-19 mRNA vaccine) targeting the SARS-CoV-2 LP.8.1 variant is produced at the company’s facility in Laval, Quebec
RN3161 is engineered to reduce fat while preserving lean mass, setting it apart from current treatment options
Biocon Foundation is also expanding its reach with this first initiative in Channapatna region
The partnership will create a first-of-its-kind, fully integrated offering for the development of mRNA drug products
Subscribe To Our Newsletter & Stay Updated
